Abstract
Background:While the efficacy of Indwelling pleural catheters for palliation of malignant pleural effusions is supported by relatively robust evidence, there is less clarity surrounding the postinsertion management.Methods:The Trustworthy Consensus-Based Statement approach was utilized to develop unbiased, scientifically valid guidance for the management of patients with malignant effusions treated with indwelling pleural catheters. A comprehensive electronic database search of PubMed was performed based on a priori crafted PICO questions (Population/Intervention/Comparator/Outcomes paradigm). Manual searches of the literature were performed to identify additional relevant literature. Dual screenings at the title, abstract, and full-text levels were performed. Identified studies were then assessed for quality based on a combination of validated tools. Appropriateness for data pooling and formation of evidence-based recommendations was assessed using predetermined criteria. All panel members participated in development of the final recommendations utilizing the modified Delphi technique.Results:A total of 7 studies were identified for formal quality assessment, all of which were deemed to have a high risk of bias. There was insufficient evidence to allow for data pooling and formation of any evidence-based recommendations. Panel consensus resulted in 11 ungraded consensus-based recommendations.Conclusion:This manuscript was developed to provide clinicians with guidance on the management of patients with indwelling pleural catheters placed for palliation of malignant pleural effusions. Through a systematic and rigorous process, management suggestions were developed based on the best available evidence with augmentation by expert opinion when necessary. In addition, these guidelines highlight important gaps in knowledge which require further study.
Original language | English (US) |
---|---|
Pages (from-to) | 229-245 |
Number of pages | 17 |
Journal | Journal of Bronchology and Interventional Pulmonology |
Volume | 27 |
Issue number | 4 |
DOIs | |
State | Published - Oct 1 2020 |
Funding
These guidelines were Commissioned and funded by the American Association for Bronchology and Interventional Pulmonology. N.M.R. has received personal fees for consultancy work and an unrestricted educational grant from Rocket Medical and was the lead investigator of the MIST-2 trial, funded by unrestricted educational grant from Roche UK. Y.C.G.L. was the lead investigator of AMPLE-1, AMPLE-2 and currently AMPLE-3. Rocket Medical provided free drainage equipment for participants in these multicenter randomized trials. He also served on the advisory board of CareFusion/BD (manufacturer of Pleurx catheter) and has received an unrestricted educational grant from Rocket Medical UK for support of AMPLE-2. In addition, he was a coinvestigator of the MIST-2 trial, funded by an unrestricted educational grant from Roche UK. A.T. was a consultant for, and receipt of royalties for intellectual property from BD Inc. (manufacturer of PleurX catheter). For the remaining authors, there is no conflict of interest or other disclosures.
Keywords
- guidelines
- indwelling pleural catheter
- malignant
- palliation
- pleural effusion
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine